Dermapharm Holding Se · XETR:DMP

Dermapharm — Q1 2020 Earnings Presentation

17 slides from Dermapharm's earnings presentation, May 19, 2020

  1. Slide 1: Investor and Analyst Conference Call Q1 2020

    INVESTOR AND ANALYST CONFERENCE CALL Q1 2020 Grünwald, 19 May 2020

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta

  3. Slide 3: Agenda

    AGENDA 1. Highlights Q1 2020 2. Financial figures Q1 2020 3. Outlook FY 2020 4. Q & A

  4. Slide 4: Agenda: Highlights Q1 2020

    AGENDA 1. Highlights Q1 2020 2. Financial figures Q1 2020 3. Outlook FY 2020 4. Q & A

  5. Slide 5: Operational and strategic highlights in Q1 2020

    Operational and strategic highlights in Q1 2020 Commitment to products “made in Germany” pays off: constant ability COVID-19 to deliver supported by classification as critical infrastructure Suitable addition to our dermatological portfolio: German specialist in Allergopharma therapeutics for desens

  6. Slide 6: Agenda: Financial figures Q1 2020

    AGENDA 1. Highlights Q1 2020 2. Financial figures Q1 2020 3. Outlook FY 2020 4. Q & A

  7. Slide 7: Dermapharm Group: Strong overall growth despite COVID-19 pandemic

    Dermapharm Group Strong overall growth despite COVID-19 pandemic Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA margin +17.7% YoY 26.7% 25.7% Significant revenue growth of 17.7% to €192.5m, due to 192.5  the global exceptional situation in branded pharmaceuticals and parallel imports 1

  8. Slide 8: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Further growth expansion driven by higher demand due to COVID-19 Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin Revenues up by 25.8% to €106.2m 44.2% 41.1%  largely based on organic growth supported by self developed products  str

  9. Slide 9: Parallel import business

    Parallel import business Growth driven by COVID-19 resulting in higher demand and intact sources of supply Revenue (€m) EBITDA (€m) Comments EBITDA Margin 3.6% 4.4% +15.4% YoY Revenues increased significantly by 15.4% to €67.5m  increased demand for parallel imported originator products  intact ab

  10. Slide 10: Herbal extracts

    Herbal extracts Decreasing demand due to COVID-19 pandemic Revenue (€m) EBITDA (€m) Comments EBITDA Margin 21.8% 20.6% -8.3% YoY Revenues decreased by 8.3% to €18.9m, comprising Euromed  weaker demand for herbal extracts, particularly in Spain and the United States due to corona pandemic 18.9 20.6

  11. Slide 11: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increased due to strong business growth Earnings before tax (EBT)(1) (€m) Comments EBT Margin 16.6% 19.1%  EBT increased by 35.3% to €36.8m (unadjusted) resulting in a higher margin of 19.1% +35.3% YoY Mainly influenced by 36.8  lower depreciation and amortis

  12. Slide 12: Strong cash flows and cash conversion

    Strong cash flows and cash conversion Reflecting strong dedication to future growth Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 38.4% 60.7%  CF from operating activities mainly influenced  by increased trade payables in Q1 2020 due to inventory build-up and b

  13. Slide 13: Balance sheet of Dermapharm Group

    Balance sheet of Dermapharm Group Balance Sheet as of 31 March 2020 (€m) Comments  Total assets increased to €1,088m (31 December 2019: €1,045m) 1,088 1,088  Non-current assets on stable level of 689m (31 December 2019: €692m)  Current assets increased to €399m Equity (31 December 2019: €353m), m

  14. Slide 14: Agenda: Outlook FY 2020

    AGENDA 1. Highlights Q1 2020 2. Financial figures Q1 2020 3. Outlook FY 2020 4. Q & A

  15. Slide 15: Growth strategy on track and informing guidance 2020

    Growth strategy on track and informing guidance 2020 positive growth in the upper Revenues 2020 single-digit percentage range vs. previous year (€700.9m) positive growth in the upper EBITDA 2020 (adjusted) single-digit percentage range vs. previous year (€177.6m) Growth rates are based on organic gr

  16. Slide 16: Agenda: Q&A

    AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A

  17. Slide 17: Investor contact

    Investor contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

Dermapharm Holding — Q1 2020 Earnings Presentation on 6ix